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Decreased Expression of Peroxiredoxins in Fuchs’
Endothelial Dystrophy
Ula V. Jurkunas,1,2,3 Ian Rawe,1 Maya S. Bitar,1,3 Cheng Zhu,1,3 Deshea L. Harris,1,3
Kathryn Colby,1,2,3 and Nancy C. Joyce1,3
PURPOSE. To compare the relative expression of peroxiredoxin
(Prx) proteins in normal human corneal endothelium with
endothelium in corneas affected by Fuchs’ endothelial dystrophy (FED) and between normal human endothelium and epithelial/stromal tissue.
METHODS. Human corneal endothelial cell-Descemet’s membrane (HCEC-DM) complexes from normal and FED corneal
buttons were dissected from the epithelium/stroma. For proteomic analysis, HCEC-DM protein extracts were separated by
using two-dimensional gel electrophoresis. Relative differences
in protein spot density was analyzed. Proteins of interest,
including Prx isoforms, were identified by MALDI-TOF (matrixassisted desorption ionization-time of flight) mass spectrometry. Western blot analysis compared the relative expression of
Prx isoforms in normal and FED endothelium and between
normal endothelium and normal epithelium/stroma. Expression of Prx-2 mRNA was compared by using real-time PCR.
RESULTS. Proteomic analysis identified differences in the relative expression of Prx isoforms between normal and FED
endothelium. Western blot analysis confirmed that expression
of Prx-2, ⫺3, and ⫺5 was significantly decreased (P ⬍ 0.05) in
FED cells. Normal HCECs expressed significantly (P ⬍ 0.05)
higher levels of Prx-2 and ⫺3 than did the epithelium/stroma.
Expression of Prx-5 was not significantly different (P ⬎ 0.05) in
the endothelium versus the epithelium/stroma. Real-time PCR
analysis revealed that Prx-2 mRNA was significantly decreased
(P ⫽ 0.027) in FED samples.
CONCLUSIONS. Prx proteins were identified in human corneal
endothelium. The fact that Prx-2 and ⫺3 were expressed at
significantly higher levels in HCEC-DM compared with the
epithelium/stroma reflects the different physiologic activities
of individual corneal cell types. Significantly decreased expression of Prx-2, ⫺3, and ⫺5 in FED may suggest an alteration in
the ability of endothelial cells to withstand oxidant-induced
damage and may be closely related to the pathogenesis of this
disease. (Invest Ophthalmol Vis Sci. 2008;49:2956 –2963) DOI:
10.1167/iovs.07-1529
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F

uchs’ endothelial dystrophy (FED) is the most common cause
of endogenous endothelial dysfunction and is the third most
common indication for corneal transplantation in the United
States.1 Even though this dystrophy was first described more than
100 years ago, the primary etiology of the endothelial cell degeneration is not yet known.2 In early stages, the dystrophy manifests
by the formation of corneal guttae or dysregulated deposition of
wide-spaced collagen between human corneal endothelial cells
(HCECs) and Descemet’s membrane (DM), with concomitant
changes in HCEC shape, size, and density.3–5 Excessive deposition
of collagen VIII has been noted in FED Descemet’s membrane,
and mutations in collagen VIII have been identified in familial,
early-onset FED.6 In the later stages of the disease, the progressive
loss of Na⫹-K⫹-ATPase pump sites is associated with the inability
of the endothelium to maintain corneal deturgescence, leading to
corneal edema.7
Recently, nuclear labeling and mRNA analysis techniques
showed that FED endothelial cell death occurs via apoptosis.8 –10 In other organ systems where cellular apoptosis is
accompanied by abnormal extracellular matrix deposition,
such as amyloid plaques in Alzheimer’s disease or drusen in
age-related macular degeneration, a strong causal factor in cell
death is oxidative stress due to excessive generation of reactive
oxygen species (ROS).11 There is mounting evidence that oxidative stress induces damage to corneal endothelium in FED.12
Previous studies by Buddi et al.13 evaluated the relative
amounts of cytotoxic byproducts of ROS in FED corneas. Although most of the differences between normal and FED were
noted in the corneal epithelium, increased amounts of nitrotyrosine, an ROS byproduct, were also noted in the FED endothelium. From the genetic standpoint, Gottsch et al.14 found
decreased transcript levels of the anti-oxidant glutathione
S-transferase-pi in FED via serial analysis of gene expression.
In initial studies from our laboratory, 2-D gel electrophoresis,
MALDI-TOF protein identification, and Western blot analysis were
used to compare protein expression between FED and normal
corneal endothelium. This analysis revealed several protein differences, one of which was marked overexpression of clusterin in
FED endothelium.15 Clusterin is a protein that protects against
oxidative stress-induced cellular apoptosis. The current studies
have further investigated the differential expression of proteins in
FED with a particular focus on proteins with antioxidant properties. Specifically, MALDI-TOF analysis of normal gels at a 15- to
30-kDa range (isoelectric point [pI], 6.0 –9.0) identified the expression of a novel class of antioxidants, peroxiredoxins (Prx).
We then investigated whether there is a difference in expression
patterns of Prx between normal and FED endothelial specimens.
In the previous 2-D gel studies, proteins were separated in the first
dimension by using a linear pH 3 to 10 gradient. In the current
studies, we changed the technique of isoelectric focusing by
employing nonlinear gradient IPG strips to expand the region of
the gel around neutral pH, thus promoting better separation of
proteins that have pIs in this area.
Prx functions by removing cellular hydrogen peroxide. Six
isotypes of Prx (1– 6) have been identified in mammals. The
subfamily of Prx 1 to 4 contains two conserved active site cysteine
(Cys) residues that use thioredoxin as an intermediate electron
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donor. Prx-5 also has two conserved active Cys residues, but does
not possess a 40-amino-acid residue segment on the C terminus
and is the smallest isoform. Prx-6 contains only one conserved Cys
residue.16 –18 Since different isoforms of Prx proteins have different cellular functions, we compared the relative expression of Prx
isoforms in normal and FED endothelium by both software analysis of 2-D gel patterns and by Western blot analysis. Real-time
PCR was used to confirm the proteomic results by comparing the
relative mRNA levels of Prx-2 between the normal and diseased
HCECs. We also used Western blot analysis to compare the relative expression of Prx isoforms in normal corneal endothelium
and in epithelial/stromal tissues.

TABLE 1. Donor Information

MATERIALS

AND

FED
HCECDM*
Pooled
Sample

2

Table 1 presents information regarding the tissue samples used in these
studies. Samples were prepared by pooling donor tissue during the
protein extraction step. Human corneal buttons were recovered from
the preservative and briefly rinsed in PBS. Under a dissecting microscope Descemet’s membrane, along with the endothelial cell layer
(HCEC-DM complex) was dissected from the cornea and placed into an
ultracentrifuge tube. The HCEC-DM complex was washed with 10 mM
HEPES (pH 7.4 buffer), before protein extraction. Samples used for 2-D
gel electrophoresis were subjected to an extra washing step with
HEPES buffer (10 mM, pH 7.4) followed by centrifugation at 5000 rpm
for 10 minutes. Protein extraction buffer ER3 (Bio-Rad, Hercules, CA)
containing 5 M urea, 2 M thiourea, 2% CHAPS, 2% SB 3-10, 40 mM Tris,
0.2% 3:10 ampholyte (Bio-Lyte; Bio-Rad), and 1 mM tributyl phosphine
(TBP) was added to the HCEC-DM sample. Samples were solubilized by
pipetting up and down, followed by incubating the tissue at room
temperature for 30 minutes. Solubilized protein was recovered by
ultracentrifugation of samples at 40,000 rpm, 21°C for 1 hour.

Age

Sex

Death-toPreservation
Time (h)†

77
78
57
62
53
62
69

M
M
F
M
F
F
M

5.8
17
21
18
20
12
17

2-D gel

Western blot
analysis

3

54
66
64
72

M
F
F
F

4

85

M

52

M

20

73
49
77
62
59
67
85
73
49
77
62

M
F
M
F
F
F
M
M
F
M
F

64
80

F
M

23
6

81
67
69
66
85
81
69

F
M
M
F
F
F
M

53
64
80
64
53
80
64
53
72
67
72
67
72
67

F
F
M
F
F
M
F
F
F
F
F
F
F
F

19
19
6
19
19
6
19
19
10
11
10
11
10
11

64
63
62
67
69
57
54
50
50
52
64
80

M
M
F
M
M
M
F
F
M
M
F
M

21
12
19
24
20
21
23
3
19
20
23
6

70
70
67

F
F
F

8
5
12

72

M

9

72
74
56

M
F
F

9
16
19

Human Tissue

Sample Preparation

Sex

1

METHODS

Donor confidentiality was maintained according to the Declaration of
Helsinki. The study was approved by the Massachusetts Eye and Ear
Institutional Review Board. Informed consent was obtained from patients undergoing corneal transplantation for FED. After surgical removal of the FED corneal buttons, they were placed in cornea preservation medium (Optisol-GS; Bausch & Lomb, Rochester, NY) at 4°C.
Two thirds of the FED corneal button was used for the study and one
third was used for histopathologic confirmation of the diagnosis. Normal human corneal buttons were obtained from the New England
Tissue Bank (Boston, MA) and the National Disease Research Interchange (Philadelphia, PA) and were used as the control. We used our
previously published criteria for obtaining normal control corneas
from the tissue banks. These criteria include using corneas with endothelial cell counts ⱖ1500.19 All normal corneas used in the study were
considered to be unsuitable for transplantation because of the lack of
blood samples from the donor for serology tests, peripheral scars or
infiltrates, pterygia, or donor age. In accepting the corneas, the overall
health of the donor before death was considered, and tissue was
rejected from donors with a history that indicated possible damage to
the endothelium. Corneas were not accepted for study if there were
too long a period (⬎24 hours) between time of death and time of
preservation, corneal guttae, or any endothelial abnormality seen on
the specular biomicroscopy; corneas from donors with glaucoma,
sepsis, or ocular infection; or corneas from donors who were on large
doses of chemotherapeutic agents. Since normal corneal buttons were
stored in preservative before sample preparation, the FED corneas
were also kept in the preservative, to negate any effects of storage
conditions on protein expression.

Age

Normal
HCEC-DM
and/or
Stroma/
Epithelium

5
6
7
8
9
10
11
12

13
14

15

16
17
18

57
78
81
63
82
50
51
69
72
61

F
M
M
M
F
F
F
F
M
F
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Use of
Samples

Real-time PCR

FED, Fuchs’ endothelial dystrophy; HCEC-DM, human corneal
endothelium and Descemet’s membrane.
* FED specimens taken during keratoplasty were placed in Optisol-GS at 4°C.
† Time (hours) between death and placement of the cornea in
Optisol-GS at 4°C.
HCEC-DM protein samples were used for 2-D gel electrophoresis and
Western blot analysis. For some studies, the remaining corneal stroma
and epithelium were cut into small pieces and homogenized. Protein
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was extracted with ER3 extraction buffer in the same manner as used
for HCEC-DM protein sample preparation. Protein concentration of the
samples was determined by modified protein assay (Bio-Rad).

2D-Gel Electrophoresis
Equal amounts of protein (Table 1, samples 1–3) were loaded onto
immobilized pH 3 to 10, nonlinear gradient, 17 cm IPG strips (Bio-Rad)
for passive rehydration over 14 hours. The use of a nonlinear IPG strip
expanded protein separation at a pI close to pH 7.0. Isoelectric focusing was performed (Protean IEF Cell; Bio-Rad) with a gradual voltage
increase up to 10,000 volts for a total of 60,000 volt-hours. Seconddimensional separation was performed using 8% to 16% precast gradient poly-acrylamide gels (BioRad). Gels (193 ⫻ 183 ⫻ 1.0 mm) were
run at 350 volts until the bromophenol blue dye disappeared. Gels
were then fixed in 10% methanol and 7% acetic acid, stained overnight
(SYPRO Ruby; Invitrogen, Carlsbad, CA), and washed in water for
1 hour before imaging.

Gel Image Capture and Analysis
Protein spots were imaged (ProExpress Proteomic Imaging system;
PerkinElmer, Boston, MA) with optimized excitation (480/80 nm) and
emission (650/150 nm) filters for the gel stain (Sypro Ruby Protein Gel
Stain; Invitrogen). Gel images were analyzed (Automatic Analysis Wizard setting in the ProFinder software; Perkin-Elmer/Nonlinear Dynamics, Newcastle-upon-Tyne, UK). Relative differences in the normalized
volume of each protein spot were compared between two pooled
samples from normal HCEC-DM and then between pooled samples from
normal and FED HCEC-DM. Protein spots of interest were chosen from the
gel spot-picking robot (ProXcision; PerkinElmer) equipped with a CCD
camera and filter sets for the stain (Sypro Ruby; Invitrogen).

MALDI-TOF Identification of Protein Spots
Gel pieces were placed in a plate (ZipPlate; Millipore, Billerica, MA) and
processed as described in the manufacturer’s protocol. In brief, the gel
plug was washed in 25 mM ammonium bicarbonate/5% acetonitrile for 30
minutes and destained with ammonium bicarbonate/50% acetonitrile two
times for 30 minutes each. Gel plugs were then dehydrated with 100%
acetonitrile for 15 minutes, rehydrated in 15 L of 25 mM ammonium
bicarbonate containing 100 ng trypsin gold (Promega, Madison, WI), and
then incubated at 30°C overnight. The C18 resin (ZipPlate; Millipore) was
then activated with 9 L acetonitrile for 15 minutes at 37°C. Peptides
were washed out of the gel plug with 180 L 0.1% trifluoroacetic acid
(TFA) for 30 minutes and then bound to the C18 resin by low vacuum
followed by washing twice with 100 L TFA in a high vacuum. The
peptides were then directly eluted onto a disposable MALDI (matrixassisted desorption ionization) target plate (PerkinElmer) by direct vacuum elution with matrix ␣-cyano-4-hydroxy cinnamic acid (␣-CHCA at 10
mg/mL; LaserBiolabs, Sophid-Antipolis, France) in 50% acetonitrile/50%
TFA. Matrix was air dried, allowing crystals to form. The MALDI plate was
then loaded (prO-TOF 2000 MALDI-TOF; PerkinElmer). The instrument
was calibrated using a two-point calibration method from a peptide calibration mix (LaserBiolabs). Sample data were acquired with a mass range
of 750 to 4500 Da. Proteins were identified by searching a local copy of
the NCBI (National Center for Biotechnology Information, www.ncbi.nih.gov) protein database (ProFound search engine; Rockefeller University,
New York, NY).

Western Blot Analysis
Equal amounts of protein from normal HCEC-DM and FED specimens
(Table 1; samples 4 –10) or from normal HCEC-DM and epithelium/
stroma samples (Table 1; samples 11–14) were loaded on 10% Bis-Tris
gels for SDS-PAGE. Positive controls consisted of cell lysate (LNCap;
Upstate Cell Signaling, Lake Placid, NY) for identification of Prx-2 and
HeLa cell lysate (Santa Cruz Biotechnology, Santa Cruz, CA) for identification of Prx-3 and ⫺5. Peptides were then electrophoretically
transferred to a polyvinylidene difluoride (PVDF) membrane (Milli-

IOVS, July 2008, Vol. 49, No. 7
pore, Bedford, MA), and nonspecific binding was blocked by incubation for 1 hour at room temperature in 5% nonfat milk diluted in PBS.
Membranes were incubated overnight at 4°C with rabbit polyclonal
anti-Prx-2 diluted 1:1000 (Upstate Cell Signaling), mouse monoclonal
anti-Prx-3 (LabFrontier, Seoul, Korea) diluted 1:600, and mouse monoclonal anti-Prx-5 (LabFrontier) diluted 1:500, rabbit polyclonal antisuperoxide dismutase-1 (SOD-1) diluted 1:100 (Santa Cruz Biotechnology), mouse monoclonal anti-vimentin diluted 1:300 (Santa Cruz
Biotechnology), or mouse monoclonal anti-␤-actin diluted 1:6000 (Sigma-Aldrich, St. Louis, MO). All dilutions were made in blocking solution. Blots were rinsed, reblocked, and exposed for 1 hour to horseradish peroxidase (HRP)-conjugated donkey anti-mouse IgG for Prx ⫺3
and ⫺5, ␤-actin, and vimentin blots (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and anti-rabbit IgG for Prx-2 and SOD-1
blots. All secondary antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. and diluted in 1:2000 in blocking solution. After washing in 0.1% Triton X-100, peptides were detected with
a chemiluminescent substrate (SuperSignal, Rockford, IL). Images were
digitally scanned and analyzed with NIH Image software version 1.61
(available by ftp at http://rsb.info.nih.gov/nih-image developed by
Wayne Rasband and provided in the public domain by the National
Center for Biotechnology Information, Bethesda, MD). Protein content
was normalized according to ␤-actin content. Experiments were repeated at least two times. Results were averaged and the standard error
was calculated. Statistical analysis using Student’s unpaired t-test was
performed with commercial software (Excel 2002; Windows XP; Microsoft, Redmond, WA). P ⬍ 0.05 was considered to be significant.

Real-Time PCR
Total RNA was extracted from normal and FED HCEC-DM complexes
(Table 1, samples 15–18) as recommended by the manufacturer
(TRIzol; Invitrogen). Samples were purified from DNA contamination
by treating them with DNase I (DNase I, Amplification Grade; Invitrogen). RNA quantity and quality were assessed by spectrophotometric
analysis. For all samples, cDNA was prepared by reverse transcription
from equal amounts of RNA in a volume of 40 L using a commercially
available kit (Promega). Relative expression levels of Prx-2 were assessed by real-time PCR using a sequence-detection system instrument
(Prism 7900 HT; Applied Biosystems [ABI], Foster, CA). Primers and
probes for Prx-2 (TaqMan Gene Expression Assays, inventoried) and
for the endogenous control ␤2-microglobulin (␤2-MG)15 (human B2M
endogenous control, FAM/MGB probe, TaqMan Endogenous Controls)
were obtained from Applied Biosystems. Samples (n ⫽ 4) were assayed
in duplicate in a total volume of 50 L, using thermal cycling conditions of 10 minutes at 95°C followed by 50 cycles of 95°C for
15 seconds and 60°C for 1 minute. No template controls were run in
each assay to confirm lack of DNA contamination in reagents used for
amplification. For data analysis, the comparative threshold cycle (CT)
method was adopted with the relative mRNA levels in normal subjects
selected as the calibrator. The CT was set in the exponential phase of
the amplification plot. To normalize the amount of target gene in each
sample, we calculated the difference in CT (⌬CT) by subtracting the
average CT of the endogenous control from that of the target gene. The
⌬⌬CT was calculated by subtracting the ⌬CT of FED samples from the
mean value of the ⌬CT of normal samples. The amount of mRNA for
Prx-2 in FED was expressed relative to the amount present in the
calibrator, using the formula 2⫺⌬⌬CT. Results were averaged and the
SEM was calculated. Statistical analysis was performed with Student’s
unpaired t-test (Excel 2002 for Windows XP; Microsoft). P ⬍ 0.05 was
considered to be significant.

RESULTS
Proteomic Analysis of Prx Isoform Expression in
FED and Normal HCEC-DM
Two-dimensional gel proteomic analysis was chosen as a
means to identify differences in protein expression between
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FIGURE 1. Representative 2-D maps
of HCEC-DM proteins pooled from
normal and FED donors. Complete
maps of ruby–stained protein spots
are shown for the pooled normal
sample (A) and the pooled FED sample (B). Outlined regions in both (A)
and (B) show areas of interest which
are shown enlarged in (C) and (D),
respectively. The position of Prx isoforms ⫺2, ⫺3, ⫺5, and ⫺6; phosphoglycerate mutase-1 (PGAM1); triosephosphate isomerase (TIM); and
carbonic anhydrase-III (CA) are indicated. The relative intensity of the
protein spots for Prx-2 and ⫺6 in (D)
were lighter than the corresponding
spots in (C). Spots corresponding to
Prx-3 and ⫺5 in (C) were not detectable in (D).

the endothelium of FED and normal donors that might reflect
important physiological changes that occur in FED endothelial
cells. Before conducting these studies, a preliminary study was
performed to determine the reproducibility of 2-D gel-based
protein separation using a nonlinear pH 3 to 10 gradient in the
first dimension. For these studies, HCEC-DM complexes were
isolated from the corneas of normal donors ranging in age from
53 to 78 years. Proteins were extracted, pooled to form two
independent samples (Table 1; pooled sample 1 and 2), and
then separated on two-dimensional gels. The resultant 2-D
images from the two pooled samples were compared by software analysis. Results showed a very similar pattern of stained
(Sypro Ruby; Invitrogen) protein spots, indicating the reproducibility of the separation technique (data not shown).
Once it was determined that the protein pattern was reproducible on 2-D gels, a study was conducted to compare the
pattern of HCEC-DM complexes isolated from FED and normal
donors. Proteins were extracted from HCEC-DM complexes
isolated from four FED corneas and corneas from two decadematched normal control subjects. Extracts were pooled to
form one FED and one normal sample (Table 1, pooled sample
3), and proteins were separated on 2-D gels as previously. The
pattern obtained from the pooled sample prepared from normal donors is shown in Figure 1A, and the pattern of the
pooled sample from the FED donors is in Figure 1B. An area of
particular interest on the 2-D gels was located within an approximate pH range of 6.0 to 9.0, and a relative molecular
weight range of 15 to 30 kDa. This area is outlined on the gel
images in Figures 1A and 1B and enlarged in Figures 1C and 1D.
Within this area of the gels was a group of protein spots that
showed similar normalized volumes. MALDI-TOF analysis identified these spots as phosphoglycerate mutase-1 (PGAM-1),
triosephosphate isomerase (TIM), and carbonic anhydrase-III
(CA-III; Table 2). These spots are identified in Figures 1C and
1D. Additional protein spots were observed in this region of

the gel prepared from the normal control samples. Among the
proteins that had a known match in the general proteomic
database were Prx-2, ⫺3, ⫺5, and ⫺6 (Table 2). Comparison of
the normalized volume of these spots showed that expression
of Prx-2 in the pooled sample from the normal control samples
was 5.033 times higher than in the FED sample. Spots corresponding to Prx-3 and ⫺5 were detected in the normal control
sample, but not in the FED sample. The normalized volume of
Prx-6 was detected 4.059 times higher in normal control samples.

Western Blot Comparison of Prx Isoform
Expression in Normal and FED HCEC-DM
Western blot analysis was next performed to verify the differential expression of Prx-2, ⫺3, and ⫺5 in normal and FED
TABLE 2. Identification of Proteins by MALDI-TOF
Protein

Molecular Mass
(kDa)

Accession
No.

Probability*

Prx 2
Prx 3
Prx 5
Prx 6
PGAM 1
TIM
CA III

22.1
27.7
16.9
25.0
28.9
26.8
29.8

P32119
P30048
P30044
P30041
P18669
P60174
P07451

1.13E-005
3.65E-005
3.18E-020
1.00E-016
6.13E-003
4.17E-005
5.12E-005

Proteins were separated on 2-D gels and identified by MALDI-TOF
following digestion. All identified proteins are available in the SWISSPROT database via the accession number. Prx, peroxiredoxin; PGAM1,
phosphoglycerate mutase 1; TIM, triosephosphate isomerase; CA III,
carbonic anhydrase III.
* E of 003 and greater is a positive match.
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HCEC-DM that was indicated by the previous 2-D gel software
analysis. The expression of Prx-6 was not pursued by Western
blot analysis due to the inability to find an antibody that
worked consistently in Western blot analysis. ␤-Actin was used
for normalization of protein load. Figure 2A presents a representative Western blot and Figure 2B presents the densitometric analysis of data averaged from seven independent samples
(Table 1, pooled samples 4 –10). HCEC-DM from FED donors
showed a statistically significant decrease in all three Prx isoforms compared with normal, decade-matched donors (Prx-2:
P ⫽ 0.0045; Prx-3: P ⫽ 0.0080; and Prx-5: P ⫽ 0.011).

Expression of SOD-1 and Vimentin in Normal
and FED HCEC-DM
To assess whether downregulation of Prx isoforms in FED is
specific, the relative expression of vimentin, an intermediate
filament protein, and the antioxidant enzyme, superoxide dismutase (SOD)-1, were compared between normal and FED
HCEC-DM samples (Table 1, pooled samples 9 and 10). Figure
3A presents a representative Western blot, whereas Figure 3B
provides densitometric data indicating that relative levels of
vimentin and SOD-1 were not significantly different (P ⬎ 0.05)
between FED and normal samples.

FIGURE 3. Western blot comparison of vimentin and SOD-1 expression in HCEC-DM complexes from FED and normal donors. (A) Representative Western blot analysis for vimentin and SOD-1. ␤-Actin was
used for normalization of protein loading. (B) Averaged densitometric
data showed no significant difference in the relative expression of
these proteins. Bars: SEM.

Western Blot Comparison of Prx Isoform
Expression in Normal HCEC-DM and
in Epithelium/Stroma
Since Prx proteins have not been identified in human cornea,
we investigated whether Prx expression is specific to corneal
endothelium or is present in the other corneal layers. Semiquantitative Western blot analysis was performed to compare
the expression of Prx isoforms in normal human corneal endothelium to epithelium/stroma. For this analysis, protein was
extracted from HCEC-DM complexes and from the remaining
epithelial/stromal tissue from normal donors aged 50 to 80
years. Extracts were pooled to yield four independent samples
(Table 1, pooled samples 11 to 14). Figure 4A presents representative Western blot images comparing the expression of
Prx-2, ⫺3, and ⫺5 in normal corneal endothelium and in the
epithelium/stroma. Figure 4B presents the densitometric analysis using ␤-actin for normalization. The average expression of
Prx-2 was 30-fold higher in HCEC-DM than in epithelium/
stroma (P ⫽ 0.0034). Prx-3 expression was not detectable in
samples prepared from the epithelium/stroma (P ⫽ 0.00062).
Prx-5 was detected in epithelial/stromal samples, but was not
significantly different from that of HCEC-DM (P ⫽ 0.5).

Real-Time PCR Comparing Prx-2 Expression
between Normal and FED HCEC-DM

FIGURE 2. Western blot analysis of Prx isoform expression in normal
and FED HCEC-DM complexes. (A) Representative Western blot analysis comparing the expression of Prx-2, ⫺3, and ⫺5 in FED and normal
corneal endothelial samples. Positive controls included LNCap cell
lysate for Prx-2 and HeLa cell lysate for Prx-3 and ⫺5. ␤-Actin was used
for normalization of protein loading. (B) Densitometric comparison of
the average expression of Prx-2, ⫺3, and ⫺5. Bars: SEM. *P ⫽ 0.0045;
**P ⫽ 0.0080; ***P ⫽ 0.011.

Proteomic analysis showed the downregulation of Prx’s in
FED-affected corneal endothelium. To investigate this difference, real-time PCR was performed to evaluate the mRNA level
of Prx-2, the most abundant Prx protein in corneal endothelium, as identified by 2-D gel electrophoresis. The PCR analysis
was performed by using previously optimized primers and
probes from Applied Biosystems. Four different pooled and
nonpooled samples were used to compare the Prx-2 mRNA
expression between FED and normal control samples. The
real-time PCR showed a downregulation of Prx-2 mRNA levels
in FED samples when normalized with the internal control

IOVS, July 2008, Vol. 49, No. 7

FIGURE 4. Western blot analysis of Prx isoform expression in normal
corneal tissue. (A) Representative Western blot comparing the expression of Prx-2, ⫺3, and ⫺5 in normal human corneal endothelium
(Endo) and epithelium/stroma (Epi/Stroma). Positive controls included
LNCap cell lysate for Prx-2 and HeLa cell lysate for Prx-3 and ⫺5.
␤-Actin was used for normalization of protein load. (B) Densitometric
comparison of average Prx isoform expression from four independent
samples (Table 1, samples 11–14). Bars: SEM. *P ⫽ 0.0034; **P ⫽
0.00062. NS, not statistically significant (P ⫽ 0.5).

␤2-MG (Fig. 5). The mean ⫾ SEM relative expression of Prx-2
mRNA in FED group (0.32 ⫾ 0.17) was significantly lower than
that in normal subjects (1.03 ⫾ 0.18; P ⫽ 0.027).
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by Western blot due to the lack of an antibody that worked
sufficiently well. In the eye, Prx-6 expression has been noted in
bovine iris stroma, lens, ciliary epithelium and its blood vessels,
and retina.22,23 In bovine cornea, Prx-6 was present in the
epithelial layer, but not found in corneal endothelium.23 The
proteomic identification of Prx-6 in the current studies requires
verification; however, the fact that Prx-6 was not detected in
bovine corneal endothelium, but was detected in humans, may
be due to species-related differences in protein expression or
to differences in detection methods. It is also possible that
Prx-1 or ⫺4 is expressed in human corneal endothelium, but
that they were not identified using our 2-D gel-based method.
In the present study, corneal stroma, and epithelium
showed lower levels of Prx expression when compared to
endothelium from the same donors. This is the first study to
indicate that Prx-2 and ⫺3 expression is significantly higher in
human corneal endothelium than in the stroma and epithelium. Prx-5 was expressed in HCECs and to a lesser extent in
epithelium/stroma; however, the difference in levels of this
Prx isoform were not statistically significant. Selective expression of certain Prx isoforms in HCEC-DM, but not in epithelium/stroma, indicates distinct functional roles of antioxidant
enzymes that reflect different physiologic activities of corneal
cell types. It is possible that significantly higher expression of
Prx-2 and ⫺3 in corneal endothelium indicates selective vulnerability of specific corneal cell types to oxidative stress.
On the proteomic level we detected a significant reduction
in Prx-2, ⫺3, and ⫺5 in FED endothelium. Tissues were used
from age-matched normal donors to eliminate any age-related
variation. The average differences in age between normal and
FED pooled samples were within a decade of each other. The
normal donors were matched by sex to patients with FED. For
studies comparing protein expression in normal and FED endothelium, extracts from FED and normal donors were pooled
to eliminate individual variations that might skew the results.
One of the limitations of our study is that some samples
contained an unequal number of pooled corneas between FED
and normal samples. Since the overall endothelial cell count
was much lower in FED samples, for the most part, more tissue
was required to be pooled for FED samples. Two different
semiquantitative methods were used to compare the relative
expression of Prx isoforms. Both the software-based 2-D gel
analysis and the Western blot analysis demonstrated a significant reduction in the expression of Prx-2, ⫺3, and ⫺5 in FED
corneal endothelium compared with age and sex-matched normal specimens. Proteomic analysis comparing the normal and
FED endothelial extracts revealed several differences in relative
protein expression patterns, the significance of which should
be further investigated. The fact that the relative expression of

DISCUSSION
Although Prx proteins have been found to be ubiquitously
expressed in human tissues, including skin, neuronal tissue,
and blood cells,18,20,21 this is the first study reporting the
expression of Prx proteins in human cornea. Results of the
proteomic analysis indicate that Prx-2, ⫺3, ⫺5, and ⫺6 are
expressed in normal corneal endothelium. Western blot studies confirmed the expression of Prx-2, ⫺3, and ⫺5 in these
cells. The 2-D gel methodology showed that Prx-2 was the most
abundantly expressed Prx protein in the endothelium, even
though Prx-5 appeared as a more intense band in the Western
blot analysis. Since the Western blot data are dependent on
many factors, one of which is the sensitivity of the primary
antibody, the spot intensity of the 2-D gels is a more accurate
representation of the relative Prx levels in the sample. As
indicated previously, expression of Prx-6 could not be verified

FIGURE 5. Real-time PCR analysis of Prx-2 isolated from normal and
FED endothelium. Mean relative expression of Prx-2 messenger RNA
(mRNA) in normal subjects and in patients with FED. Bars, SEM. *P ⫽
0.027.
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SOD-1, another antioxidant enzyme, as well as the intermediate
filament protein, vimentin, did not differ significantly between
the FED and normal tissue strongly indicates that the reduction
in expression of the Prx isoforms is specific and not the result
of a general reduction in antioxidant or total protein expression.
Proteomic analysis of normal endothelium demonstrated
that Prx-2 was the most abundant Prx isoform and thus of
potential greatest significance at the functional level. To corroborate the decrease in Prx-2 levels in FED, we compared its
expression at the gene level between normal and FED samples.
The finding that levels of Prx-2 mRNA were significantly decreased in FED samples, further substantiates the proteomic
data and indicates that the source of the differences detected
by the proteomic analysis, at least for Prx-2, stem from decreased gene transcription.
Prx proteins have various subcellular locations, reflecting
their multifunctional isoform diversity. Prx-2 is mainly a cytosolic protein that inhibits release of cytochrome c from mitochondria to cytosol and blocks hydrogen peroxide–induced
apoptosis upstream of the site of Bcl-2 action.24 In addition,
activation of NF-B induced by hydrogen peroxide is blocked
by Prx-2, indicating its role in gene transcription regulation in
response to reduction/oxidation status.25,26 Because NF-B has
been implicated in regulation of corneal endothelial cell apoptosis in response to ROS, the potential role of Prx-2 as an
endogenous inhibitor of NF-B is particularly pertinent to
HCEC physiology.27 Prx-3 (MER 5, SP-22, and AOP-1) is a
mitochondrion-specific peroxidase that uses mitochondrial thioredoxin-2 as an electron donor and provides primary antioxidant defense of the mitochondrial respiratory chain.26 Underexpression of Prx-3 has been shown to exacerbate mitochondrial macromolecule damage via membrane potential collapse, cytochrome c release, and caspase activation.28 Similar
to our findings, Prx-3 has also been noted to be under-expressed in Alzheimer’s disease (AD) and Down’s syndrome
(DS), disorders in which ROS-induced apoptosis accounts for
the neuronal cell loss.29,30 It has been postulated that the
instability of Prx-3 in the neurodegenerative disorders accounts
for the cells’ susceptibility to oxidative stress. Prx-5 has been
localized to the mitochondria, peroxisomes, and cell nucleus.
Prx-5 also has a strong antiapoptotic function and prevents
intracellular ROS production via a p53-dependent pathway.17,31,32
For future studies, it is important to correlate the downregulation of the Prx isoforms with apoptosis-related proteins,
such NF-B, caspase, and proteins involved in the p53-dependant pathways, as well as to substantiate further the role of Prx
under-expression in the apoptotic cell death seen in FED endothelium. Since FED has a notable female preponderance, it is
also important to explore Prx expression differences between
the sexes. Also, because FED is for the most part a disease of
the older population (⬎50 years of age), the changes in antioxidant expression between young and old donors may be of
significance. Whether there is a variation in Prx expression
between male and female sex and young and older donors
requires further investigation. Furthermore, the downregulation of antioxidants in FED endothelium should be correlated
with their upstream regulators, since Prx-2 underexpression is
seen on both the RNA and protein levels.
Oxidative damage via generation of ROS can lead to corneal
endothelial cell apoptosis and has been implicated in the
pathogenesis of FED.12,13 Antioxidant enzymes are critical for
regulating intracellular levels of ROS and averting the deleterious effects associated with oxidative damage. Prx proteins
constitute a potent antioxidant defense system by neutralizing
ROS. The significant decrease in Prx levels in FED-affected cells
may represent an alteration in the functioning of mechanisms
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required to combat oxidative stress related to the pathogenesis
of this disease.
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